ESMO 2024 | Engineering bacteria for tumor-targeted therapy using CRISPR-Cas

Jan Theys • 14 Sep 2024

ESMO 2024

General

Jan Theys, PhD, Maastricht University, Maastricht, Netherlands, discusses research on injecting bacteria, which are naturally home to the tumor and interact with the tumor microenvironment, into tumor-bearing animals and patients. By engineering the bacteria using advanced methods like CRISPR-Cas, they can be tailored to secrete therapeutic proteins, enzymes, and other products to target immune cells and tumor cells effectively. The controlled precision of CRISPR-Cas is showing significant promise in enhancing the therapeutic potential of bacterial-based cancer treatments. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.